Navigation Links
Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
Date:12/5/2007

ll be set based on evaluation from the first stage pharmacokinetic study using the new formulation. The second stage will evaluate the safety and tolerability of LX6171 oral suspension in subjects exhibiting AAMI and will measure the cognitive effects of LX6171 in these subjects using the Cognitive Drug Research battery, along with other psychometric instruments. The study is being conducted in Europe, with initial results expected by the end of 2008.

About LX6171

LX6171 is an orally-bioavailable small molecule developed by Lexicon scientists to inhibit a membrane protein expressed exclusively in the central nervous system and found at synaptic vesicles and presynaptic membranes of glutamatergic neurons. The protein targeted by LX6171 was identified through Lexicon's large-scale gene knockout program, the Genome5000(TM). Knockout mice lacking this protein showed improved learning and memory compared with controls. In preclinical studies, administration of LX6171 resulted in improved performance in tests of learning and memory in mice. In Phase 1 clinical trials, LX6171 was generally well tolerated at all dose levels and showed good systemic exposure.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and rheumatoid arthritis. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bris
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... TOKIO , July 13, 2014 /PRNewswire/ ... Juli in Tokio ... der firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. ... umfassenden Überblick über die fortgeschrittenen klinischen Programme ... Das Ziel der Tagung bestand darin, aktuelle ...
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... July 26 Halt Medical, Inc. announced ... been appointed to its Scientific Advisory Board.  Dr. Rubin ... to develop and implement comprehensive reimbursement strategies.  Dr. Rubin,s ... of medicine, government, and business. Currently, he is Clinical ...
... Reportlinker.com announces that a new market research report is available in its ... 2008 U.S. Diabetes Drug Delivery - ... http://www.reportlinker.com/p0236248/2008-US-Diabetes-Drug-Delivery---Patient-Perspective.html , ... This study encompasses feedback provided by U.S. diabetes patients ...
Cached Medicine Technology:Dr. Robert J. Rubin to Join Halt Board as Reimbursement Advisor 22008 U.S. Diabetes Drug Delivery - Patient Perspective 22008 U.S. Diabetes Drug Delivery - Patient Perspective 32008 U.S. Diabetes Drug Delivery - Patient Perspective 42008 U.S. Diabetes Drug Delivery - Patient Perspective 5
(Date:7/13/2014)... Genetics identifies a novel genetic and molecular ... (EoE), opening up potential new therapeutic strategies for ... EoE is a chronic inflammatory disorder of the ... to certain foods and an over-accumulation in the ... of the body,s immune system). EoE can cause ...
(Date:7/13/2014)... inexpensive, portable, microchip-based test for diagnosing type-1 diabetes ... better understand the disease, according to the device,s ... , Described in a paper to be published ... the test employs nanotechnology to detect type-1 diabetes ... the two main forms of diabetes mellitus, which ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Chromatography ... biological components from various types of biological samples ... separate the sample mixture into two phase, namely ... the mobile phase run over the stationary phase, ... the components that provide the separation of mixture. ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has ... the company’s chief executive officer has announced a new promotion ... offered at discounted prices, from 15 to 26 percent off. ... in huge demand in the current market. We are excited ... a lot of high quality products for sale. Many of ...
(Date:7/13/2014)... Vancouver, BC (PRWEB) July 13, 2014 ... creating excitement by promoting the rental of bikes for ... the historic downtown Victorian Hotel to tour the area ... day, plus tax. Bicycle enthusiasts love to call Vancouver ... many options for cycle travel and picturesque journeys through ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2
... the Y chromosome uses a neat trick to repair its ... from rotting away over evolutionary time. ,The Y chromosome, of ... makes males rather than females. ,Some scientists have suggested ... can't eliminate genetic defects in the usual way,// and broken ...
... Health Organisation said the world should be free of the ... but warned the disease could emerge in China again next ... within the next two-to-three weeks. SARS will be gone, we ... the only two areas still regarded as zones where the ...
... the onset of prostate cancer, however, finasteride may also ... men were randomized , age 55 or older to ... examination results were normal in all subjects, and prostate-specific ... Among the 4368 men in the finasteride group treated ...
... about something, let it out and it might save ... headaches internalize their anger more than those without headaches. ... study, 171 suffered from headaches. Investigators measured //trait anger ... hostility, anxiety and depression. Participants also provided information about ...
... vitamin D. ,Each year, 200,000 women in the United States ... form of the vitamin may enhance the effect of radiation ... with radiation alone to mice exposed to both radiation and ... tumor volume in those women treated //with EB 1089 was ...
... is most likely to be deadly when tumor cells spread ... a protein that may be able to predict a tumor’s ... ,Researchers from the University of Michigan Comprehensive Cancer Center are ... cancer cells to leave their original location and enter nearby ...
Cached Medicine News:Health News:Y chromosome uses trick to repair its own genes 2Health News:World SARS-free within weeks 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: